Bleeding is the most common adverse drug event associated with anticoagulants and life-threatening bleeding requires emergent reversal of the anticoagulant effect.  This session will cover reversal strategies for all anticoagulants but will focus on the direct oral anticoagulants (DOACs).  It will also cover when to resume anticoagulation after a major bleeding event.   



As a result of this educational regularly scheduled series, learners will be able to:

  1. Describe available reversal agents for oral anticoagulants
  2. Compare the data for prothrombin complex concentrates (PCC) and andexanet alfa for reversal of direct oral anticoagulants (DOACs)
  3. Identify when to resume anticoagulation after a major bleeding event
Session date: 
02/20/2020 - 12:00pm to 1:00pm CST
HSLC - Room 1325
750 Highland Ave
Madison, WI 53705
United States
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours

Please login or register to take this course.
Discloser List CME Internal Report
Anne Rose, PharmD